Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading
cause of cancer-related death in American men. Androgen deprivation therapy (ADT) has …

Inhibiting androgen receptor (AR) signaling through androgen deprivation therapy (ADT)
reduces prostate cancer (PCa) growth in virtually all patients, but response may be …

Androgen deprivation therapy (ADT) is a cornerstone treatment for locally advanced or
metastatic prostate cancer (PCa). However, its potential effects on the tumor immune …

Prostate immune system plays a critical role in the regulation of prostate cancer
development regarding androgen-deprivation therapy (ADT) and/or immunotherapy …

Immune microenvironment of prostate cancer (PCa) is implicated in disease progression.
However, previous studies have not fully explored PCa immune microenvironment. This …

Prostate cancer (PCa) is the fifth leading cause of death from cancer in men worldwide. Its
treatment remains challenging due to the heterogeneity of the tumor, mainly because of the …

Androgen deprivation therapy (ADT) is the standard therapy for men with advanced prostate
cancer (PCa). PCa often responds to ADT and enters a dormancy period, which can be …

Advanced prostate cancer patients initially respond to hormone therapy, be it in the form of
androgen deprivation therapy or second-generation hormone therapies, such as …

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage
of prostate cancer and the main cause of morbidity and mortality, which is also a potential …

Background Prostate cancer (PCa) is the most common malignant tumor in men. Although
clinical treatments of PCa have made great progress in recent decades, once tolerance to …